Finch Therapeutics Group (NASDAQ:FNCH) Trading Down 3.7%

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) shares fell 3.7% during mid-day trading on Tuesday . The stock traded as low as $12.07 and last traded at $12.07. 227 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 33,381 shares. The stock had previously closed at $12.54.

Finch Therapeutics Group Stock Performance

The company has a market cap of $19.39 million, a PE ratio of -1.19 and a beta of 1.25. The stock’s 50-day simple moving average is $6.34 and its 200 day simple moving average is $3.59.

Finch Therapeutics Group (NASDAQ:FNCH) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($3.01) EPS for the quarter.

Institutional Investors Weigh In On Finch Therapeutics Group

A hedge fund recently bought a new stake in Finch Therapeutics Group stock. Lake Street Advisors Group LLC acquired a new stake in Finch Therapeutics Group, Inc. (NASDAQ:FNCH) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 21,206 shares of the company’s stock, valued at approximately $56,000. Lake Street Advisors Group LLC owned 1.32% of Finch Therapeutics Group as of its most recent SEC filing. 21.77% of the stock is owned by institutional investors and hedge funds.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.